Best of ASCO - 2014 Annual Meeting

 

Welcome

Pediatric Solid Tumors

Pediatric Oncology

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with RET-altered cancers.

Steven G. DuBois

TPS10066

A phase I/II trial of VX15/2503 in children, adolescents, and young adults with relapsed or refractory solid tumors (ADVL1614).

Emily Gustava Greengard

e21519

A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors.

Jason R. Fangusaro

10035

A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.

Meredith Irwin

10012

AcSé-ESMART: European Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children and Adolescents–Arm D: Olaparib and irinotecan.

Susanne Andrea Gatz

10047

Alfa-feto protein (AFP) as a predictor of outcome for children with germ cell tumors: A report from the malignant germ cell international consortium.

Allison Frances O'Neill

10036

Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.

Pablo Berlanga

10018

Carcinomas in the children and young adults: A report form Children’s Oncology Group APEC14B1 study.

Rajkumar Venkatramani

e21505

Effective targeted antitumor activity of the antimicrobial agent taurolidine against relapsed/refractory neuroblastoma: Cytotoxicity, target modulation and tumor xenograft studies.

Lucy Swift

e21502

Effects of COJEC induction on neuroblastoma patient-derived xenografts (PDX).

Adriana Manas Nunez

e21503

Evaluation of outcome and prognostic factors in paediatric extraskeletal ewings sarcoma: A single institution experience.

Vijay Kumar Srinivasalu

e21507

Evaluation of the multi-kinase inhibitor regorafenib in the Pediatric Preclinical Testing Consortium osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma in vivo models.

Douglas James Harrison

10038

Factors impacting time to diagnosis in pediatric, adolescent and young adult (AYA) patients with solid tumors.

Elysia Marie Alvarez

e21515

First experience of LOXO-292 in the management of pediatric patients with RET-altered cancers.

Ulrike Gerdemann

10045

High concentration of plasma cell free DNA alerted progressive and recurrent disease in children with high risk neuroblastoma.

Yan Su

e21506

High-dose naxitamab plus stepped-up dosing of GM-CSF for high-risk neuroblastoma (HR-NB): Efficacy against histologically-evident primary refractory metastases in bone marrow (BM).

Brian H. Kushner

10024

Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.

Donald Williams Parsons

10011

Impact of low-income public insurance on survival for children and young adults with bone and soft tissue sarcomas.

Neela Lakshmi Penumarthy

10037

INFORM2 exploratory multinational phase I/II combination study of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies: INFORM2 NivEnt.

Cornelis Martinus van Tilburg

TPS10065

Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.

Cornelis Martinus van Tilburg

10010

Late toxicities, especially second malignancies, with GWAS analysis in hepatoblastoma cases treated in the Japanese study group for pediatric liver tumor protocol-2.

Eiso Hiyama

10043

Modeling and identifying therapeutic targets in Hepatoblastoma.

Jordan L. Smith

e21518

Mortality and survival rates in children and adolescents enrolled in early phase trials with a dose-finding/dose-confirmation component: An innovative therapies for children with cancer (ITCC) study.

Fernando Carceller

e21509

MRI based radiomic signature to predict treatment response to intraventricular natural killer (NK) cell infusion therapy for recurrent/refractory pediatric brain tumors.

Soumen Khatua

e21511

Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study.

Jaume Mora

10025

Off label targeted therapy use in adolescents and young adults with sarcoma.

Lisa M. Kopp

e21504

ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma.

Sharon L. Gardner

10046

Outcome of children with malignant germ cell tumors by response status at the end of induction chemotherapy.

Adriana Fonseca

10023

Outcomes of adolescent males with extracranial malignant germ cell tumors compared with children and young adults: A report from the Malignant Germ Cell Tumors International Consortium (MaGIC) group.

Furqan Shaikh

10022

Participant hopes and expectations regarding outcomes of genomic sequencing research in pediatric oncology.

Jonathan M Marron

10020

Pediatric Cancer Registry in Turkey 2009-2018 (TPOG & TPHD).

M. Tezer Kutluk

e21510

Phase 1 study of pevonedistat (MLN4924) in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).

Jennifer Foster

e21521

Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

Giles W. Robinson

10009

Population-based cancer predisposition testing as a component of newborn screening: A cost-effectiveness analysis.

Jennifer Yeh

10021

Poverty and survival in targeted immunotherapy clinical trials.

Kira O'Neil Bona

10034

Prevalence of endocrine disorders in childhood brain tumor survivors in South Korea: A nationwide population-based, longitudinal study.

Jaesung Heo

e21517

Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front–line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.

Ruth Lydia Ladenstein

10013

Randomized phase 2 trial of the combination of vincristine and irinotecan with or without temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS).

Anne Sophie Defachelles

10000

Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.

Holger N. Lode

10014

Shared dysregulation of long non-coding RNA and developmental gene networks in histone H3 K27M gliomas and PF-A ependymomas.

Lauren Sanders

e21523

Sponsorship of pediatric oncology interventional trials.

Dylan Neel

10044

Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): Results of the BEACON-Neuroblastoma randomized phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial.

Lucas Moreno

10001

The evaluation of long term follow-up (LTFU) of children with osteosarcoma: The first report from a center in a developing country.

Nurdan Tacyildiz

e21512

Tumor molecular profiling in advanced pediatric brain tumors.

Gargi D. Basu

e21516

Vincristine, irinotecan, and temozolomide as a salvage regimen for relapsed or refractory sarcoma in children and young adults.

Byung-Kiu Park

10040

What is the best therapy for grossly resected synovial sarcoma? Experience of the CWS Study Group.

Monika Scheer

10042